Overview
Overview
Bayer Group
News Overview
May 6, 2008
April 25, 2008
Werner Wenning at the Bayer AG Annual Stockholders’ Meeting
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded » more
1:32 min.
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded » more
5:33 min. 1:32 min.April 25, 2008
Annual Stockholders' Meeting
"We got off to a very good start in 2008."
Address by Werner Wenning, Chairman of the Board of Management » more
"We got off to a very good start in 2008."
Address by Werner Wenning, Chairman of the Board of Management » more
April 25, 2008
At its Annual Stockholders’ Meeting, Bayer outlines the Bayer Climate Program:
Solutions to climate change
Exhibitions, publications and a new film document the company’s commitment / Integrated measures for climate protection and for dealing with climate change / Lighthouse projects for production processes, commercial buildings and agriculture » more
Solutions to climate change
Exhibitions, publications and a new film document the company’s commitment / Integrated measures for climate protection and for dealing with climate change / Lighthouse projects for production processes, commercial buildings and agriculture » more
April 24, 2008
Interim report for the first quarter of 2008
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed » more
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed » more
April 2, 2008
Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly » more
Merger to Be Completed Shortly » more
March 31, 2008
Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit » more
Appeal will be heard by the Federal Circuit » more
March 26, 2008
Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
Subsequent Offering Period Expires on Tuesday, April 1, 2008 » more
Subsequent Offering Period Expires on Tuesday, April 1, 2008 » more
March 20, 2008
March 11, 2008
Bayer HealthCare to acquire OTC Business of Sagmel, Inc.
Acquisition strengthens Bayer Consumer Care’s Presence in Eastern Europe » more
1:10 min.
Acquisition strengthens Bayer Consumer Care’s Presence in Eastern Europe » more
1:10 min.March 3, 2008
Court decides against Bayer’s Yasmin® patent
Court decides against Bayer’s Yasmin® patent
Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted – margin target for 2009 remains unchanged / Company will consider its legal options » more
Court decides against Bayer’s Yasmin® patent
Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted – margin target for 2009 remains unchanged / Company will consider its legal options » more
February 28, 2008
Spring Financial News Conference:
Wenning: 2007 was Bayer’s most successful year to date
Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million – boosted by divestiture proceeds / Further earnings increase expected for 2008 » more
1:20 min.
Wenning: 2007 was Bayer’s most successful year to date
Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million – boosted by divestiture proceeds / Further earnings increase expected for 2008 » more
1:20 min.February 26, 2008
February 20, 2008
February 18, 2008
February 11, 2008
January 28, 2008
Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan » more
1:36 min.
First approved oral targeted therapy for metastatic RCC in Japan » more
1:36 min.January 23, 2008
Bayer establishes US special access program for Leukine® while replacing current liquid formulation
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer will replace current 500 mcg liquid formulation; aims to restore US supplies of Leukine to current levels as quickly as possible » more
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer will replace current 500 mcg liquid formulation; aims to restore US supplies of Leukine to current levels as quickly as possible » more
January 17, 2008
more News
Bookmark this page
E-mail this page
Order print version
